These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 27292780)

  • 1. Molecular Dynamics Simulation Study of the HIV-1 Protease Inhibit ion Using Fullerene and New Fullerene Derivatives of Carbon Nanostructures.
    Barzegar A; Naghizadeh E; Zakariazadeh M; Azamat J
    Mini Rev Med Chem; 2017; 17(7):633-647. PubMed ID: 27292780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor- and ligand-based study of fullerene analogues: comprehensive computational approach including quantum-chemical, QSAR and molecular docking simulations.
    Ahmed L; Rasulev B; Turabekova M; Leszczynska D; Leszczynski J
    Org Biomol Chem; 2013 Sep; 11(35):5798-808. PubMed ID: 23900343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors.
    Saleh NA
    Spectrochim Acta A Mol Biomol Spectrosc; 2015 Feb; 136 Pt C():1523-9. PubMed ID: 25459714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deformation density components analysis of fullerene-based anti-HIV drugs.
    Fakhraee S; Souri M
    J Mol Model; 2014 Nov; 20(11):2486. PubMed ID: 25388278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations.
    Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S
    J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
    Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
    Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fullerene-based inhibitors of HIV-1 protease.
    Strom TA; Durdagi S; Ersoz SS; Salmas RE; Supuran CT; Barron AR
    J Pept Sci; 2015 Dec; 21(12):862-70. PubMed ID: 26767741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation.
    Friedman SH; Ganapathi PS; Rubin Y; Kenyon GL
    J Med Chem; 1998 Jun; 41(13):2424-9. PubMed ID: 9632374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. InChI-based optimal descriptors: QSAR analysis of fullerene[C60]-based HIV-1 PR inhibitors by correlation balance.
    Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
    Eur J Med Chem; 2010 Apr; 45(4):1387-94. PubMed ID: 20116899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fullerene derivatives as dual inhibitors of HIV-1 reverse transcriptase and protease.
    Yasuno T; Ohe T; Kataoka H; Hashimoto K; Ishikawa Y; Furukawa K; Tateishi Y; Kobayashi T; Takahashi K; Nakamura S; Mashino T
    Bioorg Med Chem Lett; 2021 Jan; 31():127675. PubMed ID: 33161121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations.
    Tzoupis H; Leonis G; Durdagi S; Mouchlis V; Mavromoustakos T; Papadopoulos MG
    J Comput Aided Mol Des; 2011 Oct; 25(10):959-76. PubMed ID: 21969102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease.
    Zhu Z; Schuster DI; Tuckerman ME
    Biochemistry; 2003 Feb; 42(5):1326-33. PubMed ID: 12564936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of carbon nanotubes as HIV-1 protease inhibitors: atomistic and coarse-grained simulations.
    Cheng Y; Li D; Ji B; Shi X; Gao H
    J Mol Graph Model; 2010 Sep; 29(2):171-7. PubMed ID: 20580296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and electronic properties of new fullerene derivatives and their possible application as HIV-1 protease inhibitors.
    Ibrahim M; Saleh NA; Hameed AJ; Elshemey WM; Elsayed AA
    Spectrochim Acta A Mol Biomol Spectrosc; 2010 Feb; 75(2):702-9. PubMed ID: 20044306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMILES-based optimal descriptors: QSAR analysis of fullerene-based HIV-1 PR inhibitors by means of balance of correlations.
    Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
    J Comput Chem; 2010 Jan; 31(2):381-92. PubMed ID: 19479738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of New Cationic N,N-Dimethyl[70]fulleropyrrolidinium Iodide Derivatives as Potent HIV-1 Maturation Inhibitors.
    Castro E; Martinez ZS; Seong CS; Cabrera-Espinoza A; Ruiz M; Hernandez Garcia A; Valdez F; Llano M; Echegoyen L
    J Med Chem; 2016 Dec; 59(24):10963-10973. PubMed ID: 28002960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoronavirus Activity of Water-Soluble Pristine C
    Hurmach V; Platonov M; Prylutska S; Klestova Z; Cherepanov V; Prylutskyy Y; Ritter U
    Adv Exp Med Biol; 2021; 1352():159-172. PubMed ID: 35132600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids.
    Tanimoto S; Sakai S; Kudo E; Okada S; Matsumura S; Takahashi D; Toshima K
    Chem Asian J; 2012 May; 7(5):911-4. PubMed ID: 22378594
    [No Abstract]   [Full Text] [Related]  

  • 19. Influences of the size and hydroxyl number of fullerenes/fullerenols on their interactions with proteins.
    Wu X; Yang ST; Wang H; Wang L; Hu W; Cao A; Liu Y
    J Nanosci Nanotechnol; 2010 Oct; 10(10):6298-304. PubMed ID: 21137722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.